Cyrano Therapeutics and Resyca Announce Exclusive License Agreement for Soft Mist Nasal Spray Technology for the Treatment of Chemosensory Dysfunction
Cyrano Therapeutics, a clinical-stage regenerative medicine company pioneering the development of treatments for smell loss, and Resyca, a leading innovator in soft mist inhaler and soft nasal spray ...
Nasdaq5d
Milestone Pharmaceuticals Reports FDA PDUFA Review Date for CARDAMYST™ Nasal Spray Targeting PSVT, Plans for Mid-2025 Launch
Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results ... administration 70-mg repeat-dose regimen, of etripamil nasal spray, outside of the medically supervised setting, similar ...